This is just an update post on the million dollar a month case in Iowa that I noted makes the Iowa market weird.
USA Today reports a few more details:
a company executive shared more details during a recent presentation to the Des Moines Rotary Club. The patient is a teenage boy who has hemophilia, a genetic disorder that prevents the blood from clotting, Wellmark Executive Vice President Laura Jackson told more than 100 people who attended the Rotary meeting. She did not name him or give his hometown…
Michelle Rice, a vice president for the National Hemophilia Foundation, said she could imagine how aggressive treatment of a complicated case could lead to such costs. Rice said that when a patient’s immune system rejects the standard treatment, doctors sometimes try to overwhelm the body’s response. “You’re giving the patient massive amounts of factor on a daily basis. You’re basically trying to get the body used to the factor, so it no longer rejects it,” she said.
A coagulation disorder with complications is expensive. And regular risk-adjustment and reinsurance won’t even come close to covering the cost of a bad bleed.